CN110624065B - Application of health-preserving anticancer tablet in preparation of anti-tumor and immunoregulation disease medicines - Google Patents
Application of health-preserving anticancer tablet in preparation of anti-tumor and immunoregulation disease medicines Download PDFInfo
- Publication number
- CN110624065B CN110624065B CN201910915631.9A CN201910915631A CN110624065B CN 110624065 B CN110624065 B CN 110624065B CN 201910915631 A CN201910915631 A CN 201910915631A CN 110624065 B CN110624065 B CN 110624065B
- Authority
- CN
- China
- Prior art keywords
- tumor
- health preserving
- parts
- preserving
- health
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides application of a health-preserving anticancer tablet in preparation of an anti-tumor and immunoregulation disease medicament, and belongs to the technical field of traditional Chinese medicine application. The health preserving anticancer tablet is prepared by polysaccharide dry extract extracted from a plurality of medicinal materials; the medicinal material comprises the following components: astragalus root, wolfberry fruit, cherokee rose fruit, Siberian solomonseal rhizome, dodder seed, glossy privet fruit, white peony root, epimedium herb, liquorice and malt. The anti-tumor effect and the immunoregulation effect of the health-preserving anti-cancer tablet are researched through an in-vivo anti-tumor test and an immunoregulation test, and the health-preserving anti-cancer tablet has a certain anti-tumor effect and can improve the nonspecific immunity function, so that a reference is provided for further research on the anti-tumor effect of a subsequent traditional Chinese medicine composition.
Description
Technical Field
The invention relates to the technical field of application of traditional Chinese medicines, in particular to application of a health-preserving anticancer tablet in preparation of medicines for resisting tumor and immunoregulation diseases.
Background
Tumor refers to a new organism formed by local histiocyte hyperplasia under the action of various tumorigenic factors. According to the cellular characteristics of the new organism and the degree of harm to the organism, tumors are divided into two major categories, namely benign tumors and malignant tumors, and cancers are a general term for malignant tumors. Currently, chemotherapy, radiotherapy and hull therapy are generally used as a method for treating malignant tumors, and radiotherapy has a large side effect and damages normal cells and cancer cells at the same time, and chemotherapy generally uses antibiotics, metabolism, hormone drugs and the like and also has a large side effect. Therefore, an antitumor therapeutic method with high safety and little side effect is desired.
With the influence of various external environments such as ecological deterioration and social pressure, malignant tumors bring more and more troubles to people. Modern western medicine treatment tumor mostly adopts chemotherapy or radiotherapy, and many normal cells of a human body are killed together while cancer cells are killed, so that great pain and psychological pressure are brought to a patient. The existing method for treating tumor by traditional Chinese medicine generally has the defects of slow effect, unobvious effect and the like, so that the method provides component improvement on the basis of the existing medicament, develops a new application, can be used for resisting tumor and immunoregulation diseases, and has good curative effect.
Disclosure of Invention
Aiming at the technical problems in the related art, the invention provides the application of the health-preserving anticancer tablet in preparing the medicines for resisting tumor and immunoregulation diseases, and the health-preserving anticancer tablet has good curative effect and low toxicity.
In order to achieve the technical purpose, the technical scheme of the invention is realized as follows:
on one hand, the invention provides the application of the health preserving anticancer tablet in preparing the medicines for resisting tumor and immunoregulation diseases, and the health preserving anticancer tablet is prepared by polysaccharide dry extracts extracted from a plurality of medicinal materials; the medicinal material comprises the following components: astragalus root, wolfberry fruit, cherokee rose fruit, Siberian solomonseal rhizome, dodder seed, glossy privet fruit, white peony root, epimedium herb, liquorice and malt.
Further, the medicinal materials comprise the following components in parts by weight:
5-10 parts of astragalus membranaceus, 5-10 parts of wolfberry fruits, 5-10 parts of cherokee rose fruits, 5-10 parts of rhizoma polygonati, 5-10 parts of semen cuscutae, 5-10 parts of glossy privet fruits, 5-10 parts of white paeony roots, 10-25 parts of epimedium herbs, 1-6 parts of liquorice and 2-10 parts of malt.
Further, the preparation process of the health preserving anticancer tablet is as follows:
step 1) taking medicinal materials, adding water with 5-10 times volume, and decocting twice for 1-2 hours each time;
step 2) carrying out reduced pressure concentration on the extracting solution obtained in the step 1) at the temperature of 60-80 ℃ to obtain a concentrated solution;
step 3) precipitating the obtained concentrated solution with 70% ethanol for more than 48h, purifying the obtained precipitate with resin, and eluting with 10% ethanol to obtain health preserving polysaccharide solution;
concentrating the health preserving polysaccharide solution obtained in the step 4), recovering ethanol, and drying to obtain health preserving polysaccharide dry extract;
and 5) crushing the obtained health preserving polysaccharide dry extract, adding auxiliary materials, uniformly mixing, granulating and tabletting to obtain the health preserving anticancer tablet.
Further, the anti-tumor and immunoregulatory disease is ovarian cancer.
Furthermore, the dosage of the health preserving anticancer tablet is 0.4-1.6 g/Kg. The dosage is preferably 0.4, 0.8, 1.6 g/kg.
Further, the frequency of administration of the health preserving anticancer tablet is 1 time/d, and the administration lasts for at least 7 days.
Furthermore, the administration mode of the health preserving anticancer tablet is oral administration or intragastric administration.
Furthermore, the health-preserving anticancer tablet has an inhibiting effect on tumor activity.
Furthermore, the health preserving anticancer tablet can improve the nonspecific immunity function. Preferably mammals, such as humans, mice, etc.
The invention has the beneficial effects that:
the invention provides the application of the health preserving anticancer tablet in preparing the anti-tumor and immunoregulation disease medicine, and the health preserving anticancer tablet has a certain inhibiting effect on the tumor activity in a mouse body; the weight gain of the mice is not obviously influenced, and the toxicity is not obvious; can improve the nonspecific immunity function of mice. The anti-tumor effect and the immunoregulation effect of the health-preserving anti-cancer tablet are researched through an in-vivo anti-tumor test and an immunoregulation test, and test results show that the health-preserving anti-cancer tablet has a certain anti-tumor effect and can improve the nonspecific immunity function, so that a reference is provided for further research on the anti-tumor effect of a subsequent traditional Chinese medicine composition.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments that can be derived by one of ordinary skill in the art from the embodiments given herein are intended to be within the scope of the present invention.
Unless otherwise defined, all terms of art used hereinafter have the same meaning as commonly understood by one of ordinary skill in the art. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present invention.
Unless otherwise specified, the reagents and materials used in the present invention are commercially available products or products obtained by a known method.
Materials and methods
Tumor and animal human ovarian carcinoma cells Skov3 (Hainan Ejia Biotech Co., Ltd.). BALB/c nude mice, SPF grade, female, 4 weeks old, animal certification number: no. 43004700051084; ICR mouse, SPF grade, each half of male and female, 18 ~ 22g, animal qualification number: no.43004700052810, all purchased from Schlekschad laboratory animals, Hunan, production license number: SCXK (Xiang) 2016-.
Medicinal materials and reagents
Cyclophosphamide for injection (Jiangsu Shengdi medicine Co., Ltd., lot number: 18052925), liuwei Dihuang Wan (Jiuzhitang GmbH., lot number: 201712053), India ink (Lei Gen biol., lot number: 1009E 021).
Health preserving anticancer tablet
The medicinal materials are as follows: 5-10 parts of astragalus membranaceus, 5-10 parts of wolfberry fruits, 5-10 parts of cherokee rose fruits, 5-10 parts of rhizoma polygonati, 5-10 parts of semen cuscutae, 5-10 parts of glossy privet fruits, 5-10 parts of white paeony roots, 10-25 parts of epimedium herbs, 1-6 parts of liquorice and 2-10 parts of malt.
The preparation process of the health preserving anticancer tablet is as follows:
step 1) taking medicinal materials, adding water with 5-10 times volume, and decocting twice for 1-2 hours each time;
step 2) carrying out reduced pressure concentration on the extracting solution obtained in the step 1) at the temperature of 60-80 ℃ to obtain a concentrated solution;
step 3) precipitating the obtained concentrated solution with 70% ethanol for more than 48h, purifying the obtained precipitate with resin, and eluting with 10% ethanol to obtain health preserving polysaccharide solution;
concentrating the health preserving polysaccharide solution obtained in the step 4), recovering ethanol, and drying to obtain health preserving polysaccharide dry extract;
and 5) crushing the obtained health preserving polysaccharide dry extract, adding auxiliary materials, uniformly mixing, granulating and tabletting to obtain the health preserving anticancer tablet.
Examples
1 inhibiting effect on tumor of tumor-bearing mice:
female BALB/c nude mice, 4 weeks old, 65 were selected for the experiment. Inoculating 5X 10 subcutaneous cells under right anterior axilla6cells/mL Skov3 ovarian cancer cells 0.2 mL/cell. Selecting 50 mice successfully modeled, and randomly dividing the mice into a model control group, a low, medium and high dose group of health-preserving anti-cancer tablets and a cyclophosphamide group according to the tumor volume, wherein each group comprises 10 mice. Distilled water is fed into a model control group by intragastric administration, the low, medium and high dose groups of the health-preserving anticancer tablet are respectively fed with different doses (0.4, 0.8 and 1.6g/kg) by intragastric administration, and the cyclophosphamide group is injected into the abdominal cavity with 20mg/kg of dose of cyclophosphamide for 1 time/d for 2 weeks continuously. Weighing the weight of the mouse the next day after the last administration, killing the mouse by dislocation of cervical vertebrae, weighing the tumor, and calculating the tumor inhibition rate.
2 effects on immune function in mice:
ICR mice 18.0-22.0 g, half of female and half of male, 60 mice are selected for test, and are randomly divided into 6 groups, namely a blank control group, a model control group, a low, medium and high dose group of health-preserving anticancer tablets and a six-ingredient rehmannia pill group, wherein each group comprises 10 mice. Except for the blank control group, 5 groups were intraperitoneally injected with cyclophosphamide (100mg/kg) for 3 consecutive days. From the current day of modeling, the blank control group and the model control group are filled with stomach distilled water, the low, medium and high dose groups (0.4, 0.8 and 1.6g/kg) and the pill group (4.68g/kg) of six ingredients with rehmannia respectively filled with drugs with corresponding concentrations, each group of animals are filled with stomach according to 20mL/kg for 1 time/day,for 7 consecutive days. After the last administration for 60min, 0.1mL/10g of India ink (1: 5 dilution) was injected via the tail vein of mice. 1min and 10min after injection, 20 μ L of orbital blood is collected and dissolved in 2.0mL of 0.1% Na2CO3In the solution, absorbance (OD) was measured at 680nm, and thymus, liver and spleen were collected and weighed. Calculating thymus index, clearance index and correcting clearance index.
Thymus index (mg/10g) ═ 10 × organ weight (mg) ÷ mouse body weight (g)
Clearance index (K) (Logod)1－LogOD2)÷(t2-t1)
Note: OD1、OD2Optical density, t, of blood samples taken at different times2-t1Is the time difference between two blood samples.
3 statistical treatment
SPSS16.0 software is adopted for data statistics, and the mean value plus or minus standard deviation (X plus or minus S) is adopted for measuring data. If the normality and homogeneity of variance are met, carrying out statistical analysis by using One-way ANOVA (One-way ANOVA) and post Hoc LSD; if the normality is not met, comparative analysis is performed using the Kruskal-Wallis test. P <0.05 is statistically significant, and P <0.01 is highly statistically significant.
Results
Inhibiting effect on tumor of tumor-bearing mice
1 effect on body weight of tumor-bearing mice: animals were weighed before and weekly after dosing. Compared with a model control group, the weights of the low, medium and high dose groups and the cyclic diamide group of the health-preserving anticancer tablet are not obviously different (P is more than 0.05), which indicates that the health-preserving anticancer tablet has no influence on the weight increase of mice. See table 1 for details.
Table 1 mouse body weight (X ± S, n ═ 10)
2 inhibitory effect on mouse tumors: compared with a model control group, the tumor inhibition rates of the low-dose group and the medium-dose group of the health-preserving anticancer tablet are not significantly different (P is greater than 0.05), and the tumor inhibition rates of the high-dose group and the cyclophosphamide group of the health-preserving anticancer tablet are significantly different (P is less than 0.05), so that the health-preserving anticancer tablet has a certain inhibition effect on the tumor activity in a mouse body. See table 2 for details.
TABLE 2 Effect of Life-preserving anticancer tablets on mouse tumors (X + -S, n ═ 10)
| Group of | Tumor weight (g) | Tumor inhibition Rate (%) |
| Model control group | 1.01±0.33 | — |
| Cyclophosphamide derivatives of formula (I) | 0.48±0.19△△ | 51.89△△ |
| Low dose group | 0.91±0.26 | 9.54 |
| Middle dose group | 0.89±0.25 | 11.80 |
| High dose group | 0.70±0.23△ | 30.26△ |
Note: compared with a model control group "△"denotes P < 0.05"△△"means P < 0.01.
Effect on immune function in mice
Effect on mouse body weight 1: before and after administration, the animal body weight of the low, medium and high dose groups of the health-preserving anticancer tablet is not obviously different from that of the blank control group (P is more than 0.05), which indicates that the health-preserving anticancer tablet has no obvious influence on the weight increase of mice. See table 3 for details.
Table 3 weight comparison of mice before and after administration (X ± S, n ═ 10)
2 Effect on mouse thymus index, clearance index (K) and corrected clearance index (alpha)
Compared with a blank control group, the thymus index, the clearance index (K) and the corrected clearance index (alpha) of the model control group are all obviously reduced (P <0.01), which indicates that the mouse model with low immune function is successfully copied. Compared with a model control group, the thymus index, the clearance index and the corrected clearance index of the low-dose mice of the health-preserving anticancer tablet have no obvious difference (P is more than 0.05), and the thymus index, the clearance index and the corrected clearance index of the medium-dose and high-dose mice and the Liuwei Dihuang pill are obviously increased (P is less than 0.05), which indicates that the health-preserving anticancer tablet can improve the non-specific immunity function of the mice. See table 4 for details.
TABLE 4 Effect of Life-preserving anticancer tablets on thymus, K and alpha of mice (X + -S, n ═ 10)
Note: compared to the blank control, "+" indicates P <0.05 and "+" indicates P < 0.01. Compared with a model control group "△"denotes P < 0.05"△△"means P < 0.01.
The anti-tumor effect and the immunoregulation effect of the health-preserving anti-cancer tablet are researched through an in-vivo anti-tumor test and an immunoregulation test, and the test result shows that the health-preserving anti-cancer tablet has a certain anti-tumor effect and can improve the non-specific immunity function of a mouse.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.
Claims (4)
1. The application of the health preserving anticancer tablet in preparing the medicines for resisting tumor and immunoregulation diseases is characterized in that the health preserving anticancer tablet is prepared by polysaccharide dry extracts extracted from a plurality of medicinal materials; the medicinal materials comprise the following components in parts by weight:
5-10 parts of astragalus membranaceus, 5-10 parts of wolfberry fruits, 5-10 parts of cherokee rose fruits, 5-10 parts of rhizoma polygonati, 5-10 parts of semen cuscutae, 5-10 parts of glossy privet fruits, 5-10 parts of radix paeoniae alba, 10-25 parts of herba epimedii, 1-6 parts of liquorice and 2-10 parts of malt;
the preparation process of the health preserving anticancer tablet is as follows:
step 1) taking medicinal materials, adding water with 5-10 times volume, and decocting twice for 1-2 hours each time;
step 2) carrying out reduced pressure concentration on the extracting solution obtained in the step 1) at the temperature of 60-80 ℃ to obtain a concentrated solution;
step 3) precipitating the obtained concentrated solution with 70% ethanol for more than 48h, purifying the obtained precipitate with resin, and eluting with 10% ethanol to obtain health preserving polysaccharide solution;
concentrating the health preserving polysaccharide solution obtained in the step 4), recovering ethanol, and drying to obtain health preserving polysaccharide dry extract;
step 5), crushing the obtained health preserving polysaccharide dry extract, adding auxiliary materials, uniformly mixing, granulating and tabletting to obtain health preserving anticancer tablets;
the tumor and the immunoregulation diseases are ovarian cancer.
2. The use of the health preserving anticancer tablet of claim 1 in the preparation of anti-tumor and immunoregulatory disease drugs, characterized in that the administration mode of the health preserving anticancer tablet is oral or intragastric administration.
3. The use of the health preserving anticancer tablet as claimed in claim 1 in the preparation of drugs for treating tumor and immunoregulatory diseases, wherein the health preserving anticancer tablet has an inhibitory effect on tumor activity.
4. The use of the health preserving anticancer tablet as claimed in claim 1 in the preparation of anti-tumor and immunoregulatory disease drugs, wherein the health preserving anticancer tablet can improve the nonspecific immune function.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910915631.9A CN110624065B (en) | 2019-09-26 | 2019-09-26 | Application of health-preserving anticancer tablet in preparation of anti-tumor and immunoregulation disease medicines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910915631.9A CN110624065B (en) | 2019-09-26 | 2019-09-26 | Application of health-preserving anticancer tablet in preparation of anti-tumor and immunoregulation disease medicines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110624065A CN110624065A (en) | 2019-12-31 |
| CN110624065B true CN110624065B (en) | 2021-12-14 |
Family
ID=68974185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910915631.9A Active CN110624065B (en) | 2019-09-26 | 2019-09-26 | Application of health-preserving anticancer tablet in preparation of anti-tumor and immunoregulation disease medicines |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110624065B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1042835A (en) * | 1989-12-23 | 1990-06-13 | 衡阳中药厂 | A kind of manufacture method of medicine of enhancing body function |
| CN101869680A (en) * | 2008-04-24 | 2010-10-27 | 紫光古汉集团股份有限公司 | New application of composition for nourishing kidney, tonifying energy, nourishing brain and allaying excitement |
| CN105267793A (en) * | 2015-11-26 | 2016-01-27 | 紫光古汉集团股份有限公司 | New application of traditional Chinese medicine composition |
-
2019
- 2019-09-26 CN CN201910915631.9A patent/CN110624065B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1042835A (en) * | 1989-12-23 | 1990-06-13 | 衡阳中药厂 | A kind of manufacture method of medicine of enhancing body function |
| CN101869680A (en) * | 2008-04-24 | 2010-10-27 | 紫光古汉集团股份有限公司 | New application of composition for nourishing kidney, tonifying energy, nourishing brain and allaying excitement |
| CN105267793A (en) * | 2015-11-26 | 2016-01-27 | 紫光古汉集团股份有限公司 | New application of traditional Chinese medicine composition |
Non-Patent Citations (3)
| Title |
|---|
| ‘古汉养生精’对小鼠免疫功能和肿瘤生长的影响以及32例肿瘤患者细胞免疫状况的作用;张力群等;《北京中医》;19961231(第3期);第52页第2-5节、第53页 * |
| 中西医结合治疗化疗后白细胞减少症的临床观察;李莉等;《黑龙江医学》;19971231(第03期);第27页 * |
| 温阳散郁法对小鼠H_(22)肝癌细胞凋亡及增殖关系的实验研究;郭勇义;《中医研究》;20080930(第09期);第11-14页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110624065A (en) | 2019-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2013071727A1 (en) | Anti-tumor traditional chinese medical composition | |
| CN101850032B (en) | Anti-tumor traditional Chinese medicine composition and preparation method and application thereof | |
| CN103550506A (en) | Traditional Chinese medicine composition cooperatively used in radiotherapy | |
| CN102861193A (en) | Traditional Chinese medicine composition for treating gastric cancer | |
| CN102389559B (en) | Traditional Chinese medicine composition and application as radiotherapy sensitizer | |
| CN110624065B (en) | Application of health-preserving anticancer tablet in preparation of anti-tumor and immunoregulation disease medicines | |
| CN105287944A (en) | Traditional Chinese medicine composition for adjuvant therapy of thyroid cancer | |
| CN102872385B (en) | Compound Chinese medicinal composition for treating advanced gastric cancer and preparation method and application thereof | |
| CN107854565B (en) | Anti-radiation traditional Chinese medicine composition | |
| CN102125571A (en) | Dammarane aglycon compound and application thereof | |
| CN104189782A (en) | Anti-tumor medicament composition | |
| CN102423384B (en) | Traditional Chinese drug preparation for treating lung cancer, and preparation method thereof | |
| CN103191267B (en) | Traditional Chinese medicine composition for treating liver cancers | |
| CN104689088B (en) | A kind of Chinese medicine preparation and preparation method of prevention immunosenescence | |
| CN103191268B (en) | Traditional Chinese medicinal composition for treating lung cancer | |
| CN110624079A (en) | A Chinese medicinal composition for improving cancer-induced fatigue and tumor radiotherapy and chemotherapy reaction | |
| CN104013680A (en) | Extractive for preparing astragalus membranaceus-ligustrum healthy-qi-reinforcing preparation | |
| CN106619765A (en) | Pharmaceutical composition containing Marsdenia tenacissima extract product | |
| CN108434222B (en) | Traditional Chinese medicine compound preparation for treating ovarian tumor and application thereof | |
| CN116832129A (en) | Traditional Chinese medicine composition for resolving masses and eliminating tumors as well as preparation method and application thereof | |
| CN106039041B (en) | Traditional Chinese medicine composition for preventing and treating nuclear radiation injury | |
| CN104189846A (en) | Traditional Chinese medicine composition used as radiotherapy and chemotherapy sensitizing agent and preparation method thereof | |
| CN117982557A (en) | Use of fermented soya bean ginger or its extract and its composition | |
| CN115501314A (en) | Compound traditional Chinese medicine composition for inhibiting tumor liver metastasis and preparation method and application thereof | |
| CN113995820A (en) | Chinese medicinal preparation for treating malignant tumor and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: No. 1 Luojin Bridge, Yanfeng District, Hengyang City, Hunan Province, 421000 Applicant after: Guhan traditional Chinese Medicine Co.,Ltd. Address before: No. 1 Luojin Bridge, Yanfeng District, Hengyang City, Hunan Province, 421000 Applicant before: TUS-GUHAN GROUP HENGYANG TRADITIONAL CHINESE MEDICINE CO.,LTD. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |